XML 105 R49.htm IDEA: XBRL DOCUMENT v2.4.1.9
Significant Accounting Policies (Details) (USD $)
12 Months Ended 1 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Oct. 31, 2010
Feb. 28, 2007
Loss Attributable to Noncontrolling Interest          
Noncontrolling interest ownership percentage 74.00%us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners        
Net loss attributable to non-controlling interest $ 138,000us-gaap_NetIncomeLossAttributableToNoncontrollingInterest $ 252,000us-gaap_NetIncomeLossAttributableToNoncontrollingInterest $ 84,000us-gaap_NetIncomeLossAttributableToNoncontrollingInterest    
Concentrations of Credit Risk          
Concentration of risk, cash and cash equivalents 6,000,000us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents 45,900,000us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents      
Revenue Recognition          
Revenues 1,300,000us-gaap_Revenues 5,100,000us-gaap_Revenues 5,500,000us-gaap_Revenues    
Product return period 18 months        
Product return period prior to label expiration date 6 months        
Product return period after label expiration date 12 months        
Accrual for product returns 3,300,000mdco_AccrualForProductReturns 2,400,000mdco_AccrualForProductReturns      
Allowance for chargebacks 44,400,000mdco_AllowanceForChargebacks 25,000,000mdco_AllowanceForChargebacks      
Fees for service discount settlement period 60 days        
Fee-for-service accurals and allowances 900,000mdco_FeeForServiceAccuralsAndAllowances 3,100,000mdco_FeeForServiceAccuralsAndAllowances      
Advertising Costs          
Advertising expense 1,100,000us-gaap_AdvertisingExpense 400,000us-gaap_AdvertisingExpense 200,000us-gaap_AdvertisingExpense    
Research and Development [Abstract]          
Reimbursement Revenue 9,500,000us-gaap_ReimbursementRevenue        
Angiomax [Member]          
Revenue Recognition          
Deferred revenue 600,000us-gaap_DeferredRevenue
/ us-gaap_ProductOrServiceAxis
= mdco_AngiomaxMember
800,000us-gaap_DeferredRevenue
/ us-gaap_ProductOrServiceAxis
= mdco_AngiomaxMember
     
Minimum selling price 50.00%mdco_RevenueRecognitionMultipleDeliverableArrangementsDeterminationofSellingPricePercentage
/ us-gaap_ProductOrServiceAxis
= mdco_AngiomaxMember
       
Cleviprex [Member]          
Revenue Recognition          
Deferred revenue 5,800,000us-gaap_DeferredRevenue
/ us-gaap_ProductOrServiceAxis
= mdco_CleviprexMember
       
Increase in net sales 700,000mdco_IncreaseDecreaseinNetSales
/ us-gaap_ProductOrServiceAxis
= mdco_CleviprexMember
       
Orbactiv [Member]          
Revenue Recognition          
Revenues 800,000us-gaap_Revenues
/ us-gaap_ProductOrServiceAxis
= mdco_OrbactivMember
       
Argatroban [Member]          
Revenue Recognition          
Increase in net sales 1,600,000mdco_IncreaseDecreaseinNetSales
/ us-gaap_ProductOrServiceAxis
= mdco_ArgatrobanMember
       
Integrated Commercialization Solutions, Inc [Member]          
Revenue Recognition          
Revenue agreement additional renewal period 1 year        
Revenue agreement renewal notice period 90 days        
Revenue agreement termination notice period 180 days        
Distribution agreement payment period       45 days 30 days
Distribution agreement payment period if pay by wire transfer       49 days  
Integrated Commercialization Solutions, Inc [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]          
Concentrations of Credit Risk          
Concentration risk, percentage 95.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= mdco_IntegratedCommercializationSolutionsIncMember
89.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= mdco_IntegratedCommercializationSolutionsIncMember
90.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= mdco_IntegratedCommercializationSolutionsIncMember
   
Integrated Commercialization Solutions, Inc [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentrations of Credit Risk          
Concentration risk, percentage 95.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= mdco_IntegratedCommercializationSolutionsIncMember
92.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= mdco_IntegratedCommercializationSolutionsIncMember
     
Accounts receivable, gross $ 193,400,000us-gaap_AccountsReceivableGross
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= mdco_IntegratedCommercializationSolutionsIncMember
$ 120,900,000us-gaap_AccountsReceivableGross
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= mdco_IntegratedCommercializationSolutionsIncMember